Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metronomic Capecitabine in Stage III Gastric Cancer
Sponsor: Fudan University
Summary
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Official title: Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
722
Start Date
2024-03-10
Completion Date
2029-03-10
Last Updated
2024-07-08
Healthy Volunteers
No
Conditions
Interventions
Metronomic capecitabine group
500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
Observation
observation
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China